New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD
- PMID: 18456311
- DOI: 10.1016/j.pbb.2008.03.016
New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD
Abstract
Attention deficit hyperactivity disorder (ADHD) is a common childhood psychiatric condition that is effectively treated by catecholaminergic drugs with a variety of different mechanisms and the SH rat is frequently used as a model of this disorder. In vivo microdialysis in freely-moving rats has been employed extensively to provide a better understanding of the pharmacodynamics of drugs at their sites of action. In this review, these three topics are brought together to explore the contribution of in vivo microdialysis studies in spontaneously hypertensive (SH) rats to our understanding of the neurochemical deficits in this rat strain and the actions of ADHD drugs on catecholaminergic function in the prefrontocortex (PFC), striatum and nucleus accumbens. What is revealed is that basal efflux of norepinephrine in the PFC is attenuated, whilst striatal and mesolimbic dopaminergic neurotransmission is hyperfunctional; the latter observation fits closely with the hyperactive phenotype of the SH rat. Furthermore, experiments performed with the enantiomers of amphetamine and threo-methylphenidate demonstrate that pharmacodynamic effects of drugs reported from experiments in outbred rat strains, e.g. Sprague-Dawleys, do not necessarily translate to the SH rat. When the findings are compared with the clinical efficacy of drugs used in treating ADHD, they indicate that the most efficacious drugs powerfully increase both norepinephrinergic and dopaminergic neurotransmission.
Similar articles
-
Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type.Neuroscience. 2010 Jun 2;167(4):1183-91. doi: 10.1016/j.neuroscience.2010.02.073. Epub 2010 Mar 6. Neuroscience. 2010. PMID: 20211696
-
The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.Neuropharmacology. 2009 Dec;57(7-8):608-18. doi: 10.1016/j.neuropharm.2009.08.020. Epub 2009 Sep 15. Neuropharmacology. 2009. PMID: 19761781 Review.
-
Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder.Pharmacol Biochem Behav. 2006 Mar;83(3):380-90. doi: 10.1016/j.pbb.2006.02.018. Epub 2006 Mar 6. Pharmacol Biochem Behav. 2006. PMID: 16580713
-
The usefulness of the spontaneously hypertensive rat to model attention-deficit/hyperactivity disorder (ADHD) may be explained by the differential expression of dopamine-related genes in the brain.Neurochem Int. 2007 May;50(6):848-57. doi: 10.1016/j.neuint.2007.02.005. Epub 2007 Mar 1. Neurochem Int. 2007. PMID: 17395336
-
Spontaneously hypertensive rat (SHR) as an animal model for ADHD: a short overview.Rev Neurosci. 2011;22(3):365-71. doi: 10.1515/RNS.2011.024. Epub 2011 May 13. Rev Neurosci. 2011. PMID: 21591908 Review.
Cited by
-
The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.J Child Adolesc Psychopharmacol. 2015 Jun;25(5):402-14. doi: 10.1089/cap.2014.0176. Epub 2015 Feb 18. J Child Adolesc Psychopharmacol. 2015. PMID: 25692608 Free PMC article. Clinical Trial.
-
Performance deficits of NK1 receptor knockout mice in the 5-choice serial reaction-time task: effects of d-amphetamine, stress and time of day.PLoS One. 2011 Mar 7;6(3):e17586. doi: 10.1371/journal.pone.0017586. PLoS One. 2011. PMID: 21408181 Free PMC article.
-
The Effects of Methylphenidate on Goal-directed Behavior in a Rat Model of ADHD.Front Behav Neurosci. 2015 Nov 25;9:326. doi: 10.3389/fnbeh.2015.00326. eCollection 2015. Front Behav Neurosci. 2015. PMID: 26635568 Free PMC article.
-
Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases.Neuropsychiatr Dis Treat. 2015 Nov 19;11:2909-12. doi: 10.2147/NDT.S87359. eCollection 2015. Neuropsychiatr Dis Treat. 2015. PMID: 26640376 Free PMC article.
-
The effects of the neurotoxin DSP4 on spatial learning and memory in Wistar rats.Atten Defic Hyperact Disord. 2012 Jun;4(2):93-9. doi: 10.1007/s12402-012-0076-4. Epub 2012 May 15. Atten Defic Hyperact Disord. 2012. PMID: 22585442 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous